Last reviewed · How we verify
NCT06708130
Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
trial in Allogeneic Hematopoietic Stem Cell Transplantation in 3,000 participants. Currently enrolling.
31 December 2031
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 May 2021 |
| Primary completion | 31 December 2031 |
| Estimated completion | 31 December 2031 |
| Sites | 3 locations across China |
Conditions studied
- Allogeneic Hematopoietic Stem Cell Transplantation — all drugs for Allogeneic Hematopoietic Stem Cell Transplantation →
Sponsor
Ruijin Hospital
Who can join
Eligibility, any sex, with Allogeneic Hematopoietic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical observational studies using epidemiologic theories and methods. Through the collection of various clinically relevant data, specific outcomes are evaluated in hematologic transplant patients, providing high quality real-world data for clinical practice, informing public health decision-making, and reducing the burden of disease
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Wang L, Huang J, Jiang C, Huang M, et al · · 2026 · cited 5× · PMID 40705849 · DOI 10.1093/cid/ciaf410
Verify or expand the search:
- PubMed search for NCT06708130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allogeneic Hematopoietic Stem Cell Transplantation
Currently open trials in the same condition.
- NCT07013370 — Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H · recruiting
- NCT07094464 — Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation · Phase 1 · active not recruiting
- NCT03357172 — Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transpl · NA · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06708130 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06708130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing